A recent study showed that although serum cholesterol reduction did not significantly affect the rate of adenocarcinoma development in the PTEN-null transgenic mouse model of prostate cancer [78], it lowered intraprostatic androgens and slowed tumor growth. Here, PTEN is linked to prostate carcinoma.